drugset / Trial / NCT00488189

Study Evaluation Tazocin Intervention

NCT00488189

Phase 4 Completed 134 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedSingle-groupOpen-labelHealth-services research

Summary

This is an antibiotic intervention study to determine the value of using piperacillin/tazobactam in reducing the cases of ESBL producing E. coli or K. pneumoniae colonization and infection.

Timeline

Start
2007-05
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Piperacillin Small molecule
Comparator Tazobactam Small molecule